Element Health Labs
Peptide Library / Ipamorelin
Peptide IQ

Ipamorelin

Growth hormone secretagogue (ghrelin/growth hormone secretagogue receptor agonist)

This page is educational only and is not medical advice. It is not an endorsement to use this compound. See the Educational Disclaimer for details.

Quick Answer

A synthetic peptide designed to stimulate growth hormone release via the ghrelin receptor pathway, often discussed alongside CJC-1295 in research/community contexts as a combination.

Why People Are Interested

Discussed as the "gentler" growth-hormone secretagogue — its proposed selectivity for GH release over cortisol and other hormones is the specific reason it comes up so often as an alternative to older compounds in this class.

What People Hope It May Do

GH-release benefits for body composition and recovery with fewer side effects than older secretagogues, based on an early pharmacological selectivity argument. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)

Potential / Research Areas

Growth hormone secretion selectivity

Potential body-composition and recovery-related research questions (largely community-driven interest)

How It May Work

Activates the growth hormone secretagogue receptor, prompting pulsatile growth hormone release from the pituitary, with a proposed selectivity profile intended to minimize effects on other hormones (e.g., cortisol) compared to older secretagogues — this selectivity claim originates in early pharmacology research and should be attributed and hedged accordingly, not stated as settled fact.

What Human Research Shows

Limited public large-scale controlled trial data. Related secretagogue-class compounds have more extensive study in specific diagnostic contexts, but that should not be conflated with evidence specific to ipamorelin itself.

What Preclinical Research Shows

Receptor-binding and endocrine pharmacology studies form the bulk of the available preclinical picture.

Element Evidence Snapshot™

Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.

Human ResearchLimited
Preclinical ResearchModerate
Clinical Trial ActivityNone Identified
Real-World InterestModerate
Regulatory StatusNot Approved
Research MomentumLimited

"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.

What People Report

Real-World / Anecdotal Experience — in development. Element Health Labs hasn't yet compiled a reliable synthesis of public anecdotal reports for Ipamorelin. When this section is live, it will summarize commonly reported themes from public discussion, clearly separated from the scientific evidence above. Anecdotal reports are not clinical evidence, and individual experiences vary. See Real Experiences for how this is being built.

What Experts Are Saying

Curated commentary specific to Ipamorelin is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.

Clinical Trials

For the current, authoritative list of registered trials involving Ipamorelin, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.

Potential Risks & Side Effects

No comprehensive controlled human safety database exists publicly at drug-approval scale. General hormone-axis manipulation carries risks that require licensed medical supervision to assess — not something to characterize as safe or unsafe in a general-audience article without that caveat.

Regulatory Status

Not FDA-approved as a standalone product for any indication.

What We Still Don't Know

Whether that selectivity claim holds up in large, independent human trials, and what the real-world tradeoffs of sustained use look like.

Limitations of Evidence

Sparse controlled human trials; much of the public discussion is anecdotal rather than clinical-trial-derived.

Key Takeaway. Ipamorelin is a real area of scientific and public interest — but interest, mechanism plausibility, and proof are three different things. As of this review: human research is limited, preclinical research is moderate, and its regulatory status is Not Approved. Read the sections above — not just this summary — before forming a view, and talk to a licensed healthcare provider before making any health decision.

Keep Researching

Sources. Key studies and full references for this entry are still being compiled and verified — see data/peptides/ipamorelin.md in the project repo for the current compliance-review status. This page will not publish claims backed by unverified or fabricated citations.
Last reviewed: 2026-08-15